Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?

Alessandro Rizzo, A. Ricci
{"title":"Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?","authors":"Alessandro Rizzo, A. Ricci","doi":"10.1080/23808993.2022.2075724","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction Hepatocellular carcinoma (HCC) remains an important cause of cancer-related death, representing the sixth most commonly diagnosed malignancy worldwide. Novel systemic treatment options have recently emerged for advanced diseases, including immune checkpoint inhibitors (ICIs), as monotherapy or in combination with other anticancer agents. However, several questions remain unanswered, including the identification of predictors of response to immunotherapy in this setting. Areas Covered Herein, we will provide a critical overview of current knowledge regarding predictive biomarkers of response to ICIs in HCC patients. A literature search was conducted in December 2021 of PubMed/Medline, Cochrane library, and Scopus databases. Expert Opinion Several critical issues regarding the role of ICIs in advanced HCC remain unsolved, with the identification of predictive biomarkers representing an unmet need. Further efforts aimed at identifying reliable predictors and the effective role of PD-L1 status, TMB, MSI, and other biomarkers are warranted.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2022-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Precision Medicine and Drug Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23808993.2022.2075724","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

ABSTRACT Introduction Hepatocellular carcinoma (HCC) remains an important cause of cancer-related death, representing the sixth most commonly diagnosed malignancy worldwide. Novel systemic treatment options have recently emerged for advanced diseases, including immune checkpoint inhibitors (ICIs), as monotherapy or in combination with other anticancer agents. However, several questions remain unanswered, including the identification of predictors of response to immunotherapy in this setting. Areas Covered Herein, we will provide a critical overview of current knowledge regarding predictive biomarkers of response to ICIs in HCC patients. A literature search was conducted in December 2021 of PubMed/Medline, Cochrane library, and Scopus databases. Expert Opinion Several critical issues regarding the role of ICIs in advanced HCC remain unsolved, with the identification of predictive biomarkers representing an unmet need. Further efforts aimed at identifying reliable predictors and the effective role of PD-L1 status, TMB, MSI, and other biomarkers are warranted.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肝细胞癌免疫治疗反应的预测因素:有什么前景吗?
摘要简介肝细胞癌(HCC)仍然是导致癌症相关死亡的重要原因,是全球第六大最常见的恶性肿瘤。最近出现了针对晚期疾病的新的全身治疗选择,包括免疫检查点抑制剂(ICIs),作为单一疗法或与其他抗癌药物联合使用。然而,有几个问题仍未得到解答,包括在这种情况下确定免疫疗法反应的预测因素。本文涵盖的领域,我们将对HCC患者对ICIs反应的预测性生物标志物的当前知识进行批判性概述。2021年12月,对PubMed/Medline、Cochrane图书馆和Scopus数据库进行了文献检索。专家意见关于ICIs在晚期HCC中的作用的几个关键问题仍未解决,预测性生物标志物的鉴定代表了未满足的需求。需要进一步努力,以确定PD-L1状态、TMB、MSI和其他生物标志物的可靠预测因素和有效作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.30
自引率
0.00%
发文量
9
期刊介绍: Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.
期刊最新文献
Precision Medicine Paradigms in Allergic Rhinitis: Navigating Immunotherapy and Digital Healthcare Advanced laboratory techniques in diffuse large B-cell lymphoma treated with CAR-T: the role for pathologists Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma Advances in the field of developing biomarkers for re-irradiation: a how-to guide to small, powerful data sets and artificial intelligence Shorting vorasidenib for IDH mutant low-grade glioma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1